Isomorphic Labs, leveraging AI breakthroughs from DeepMind, is on the brink of human clinical trials for cancer drugs. With major pharma partnerships, the future of drug design looks promising!
In a surprising turn of events, Regeneron has announced its acquisition of 23andMe for $256 million following the company's bankruptcy. The pharma giant aims to leverage 23andMe's vast customer data for drug discovery while prioritizing privacy and security.
